Imidex and Spesana collaborate over impact of AI in lung nodule and mass detection
James Spargo | July 12, 2024 | News story | Research and Development | Imidex, Oncology, Spesana, artificial intelligence, cancer detection, lung cancer
Personalised medicine technology company Spesana and Imidex, developer of computer-aided detection technology, have announced a strategic partnership to research AI’s impact on lung nodule and mass detection in lung cancer.
The companies will combine their technologies – Imidex’s VisiRad XR, an AI detection algorithm, and Spesana’s medical data and clinical workflow platform – in a clinical trial design. The aim is to study how many additional lung masses and nodules can be detected in existing chest x-rays, and to then ‘quantify downstream lung cancer detection rates, identify at-risk patients for clinical trials through screening and evaluate the potential use of liquid biopsies resulting from nodule detection on chest x-rays,’ according to Imidex’s press release.
“Imagine a world where lung cancer is detected early, treatment begins sooner and patients have a fighting chance for a better prognosis,” said Carla Balch, CEO of Spesana. “Our partnership now extends the comprehensive nature of precision medicine by adding imaging diagnostics to our deep existing molecular diagnostic capabilities.”
“Imidex is deploying our leading FDA 510(k)-cleared algorithm for lung nodule and mass detection to improve the screening of potential future lung cancer patients,” said Wes Bolsen, CEO of Imidex. “Our collaboration with Spesana will equip healthcare providers and pharmaceutical companies with the tools they need to identify lung nodules earlier, improve patient outcomes and optimise healthcare resources.”
James Spargo
Related Content
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
Graphene-based biosensor to support new lung cancer screening test
HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and …
FDA approves diagnostic tool for MET-targeted lung cancer therapy
The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay …
